Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Change in Account Payables (2022 - 2025)

Historic Change in Account Payables for Coeptis Therapeutics Holdings (COEP) over the last 4 years, with Q3 2025 value amounting to -$241188.0.

  • Coeptis Therapeutics Holdings' Change in Account Payables fell 6417.51% to -$241188.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$346606.0, marking a year-over-year decrease of 15314.1%. This contributed to the annual value of -$149935.0 for FY2024, which is 11135.29% down from last year.
  • Coeptis Therapeutics Holdings' Change in Account Payables amounted to -$241188.0 in Q3 2025, which was down 6417.51% from -$91832.0 recorded in Q2 2025.
  • Over the past 5 years, Coeptis Therapeutics Holdings' Change in Account Payables peaked at $937694.0 during Q4 2023, and registered a low of -$241188.0 during Q3 2025.
  • Its 4-year average for Change in Account Payables is $43569.6, with a median of $23671.0 in 2022.
  • Its Change in Account Payables has fluctuated over the past 5 years, first surged by 54542.69% in 2023, then plummeted by 26930.46% in 2024.
  • Coeptis Therapeutics Holdings' Change in Account Payables (Quarter) stood at -$228851.0 in 2022, then surged by 509.74% to $937694.0 in 2023, then plummeted by 85.55% to $135521.0 in 2024, then crashed by 277.97% to -$241188.0 in 2025.
  • Its Change in Account Payables stands at -$241188.0 for Q3 2025, versus -$91832.0 for Q2 2025 and -$149107.0 for Q1 2025.